Aplastic anemia before bone marrow transplantation and antilymphocyte globulin

Acta Haematologica

Volumn 103, Issue 1, 2000, Pages 11-15

  Heimpel, Hermann ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Aplastic anemia; Prognostic factor; Secondary leukemia

Indexed keywords

ANDROGEN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HORMONAL THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MYELODYSPLASIA; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLENECTOMY;

EID: 0034013606     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040998     Document Type: Review

References (54)

1. Speck B, Gluckman E, Haak HL, et al: Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet 1977;ii:1145-1148.
2. Williams DM, Lynch RE, Cartwright GE: Prognostic factors in aplastic anemia. Clin Haematol 1978;7:467-474.
3. Davis S, Ruben AD: Treatment and prognosis of aplastic anemia. Lancet 1972;i:871.
4. Sanchez Medal L, Gomez Leal A, Duarte L, et al: Anabolic androgenic steroids in the treatment of acquired aplastic anemia. Blood 1969; 34:283-300.
5. Najean Y, Bernard J, Wainberger M, et al: Evolution et pronostic de pancytopenies idiopathiques. Etude de 116 observations. Nouv Rev Fr Hématol 1965;5:639-656.
6. Heimpel H, Rehbock C, Van Eimeren W: Verlauf und Prognose der Panmyelopathie und der isolierten aplastischen Anämie: Eine retrospective Studie an 70 Patienten. Blut 1975;30: 235-254.
7. Camitta B, Thomas ED, Nathan DG, et al: Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976;48:63-70.
8. Najean Y, Pecking A: Prognostic factors in acquired aplastic anemia. A study of 352 cases. Am J Med 1979;67:564-571.
9. Mir MA, Geary CG: Aplastic anemia: An analysis of 174 patients. Postgrad Med J 1980;56: 322-326.
10. Li FP, Alter BP, Nathan DG: The mortality of acquired aplastic anemia in children. Blood 1972;40:153-162.
11. Weiss G: Verlauf und Prognose der erworbenen Panmyelopathie: doct thesis, Ulm, 1980.
12. Schrezenmeier H, Marin P, Raghavachar A, et al: Relapse of aplastic anemia after immunosuppressive treatment: A report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993;85: 371-377.
13. Camitta B, O'Reilly RJ, Sensenbrenner L, et al: Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood 1983;62:883-888.
14. Champlin R, Ho W, Gale RP: Antithymocyte globulin treatment in patients with aplastic anemia: A prospective randomized trial. N Engl J Med 1983;308:113-118.
15. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al: Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cydosporine. N Engl J Med 1991;324:1297-1304.
16. Lewis SM: Course and prognosis in aplastic anemia. Br Med J 1965;i:1027-1031.
17. Te Velde J, Haak HL: Histology of bone marrow failure, a follow-up study in aplastic anaemia. Hämatol Bluttransfus 1979;24:15-25.
18. Lynch RE, Williams DM, Reading JC, et al: The prognosis in aplastic anemia. Blood 1975; 45:517-528.
19. Frisch B, Lewis SM: The bone marrow in aplastic anaemia: Diagnostic and prognostic features. J Clin Pathol 1974;27:231-241.
20. Camitta BM, Rappeport JM, Parkman R, Nathan DG: Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood 1975;45:355-363.
21. Alter BP, Potter NU. Li FP: Classification and aetiology of the aplastic anemias. Clin Haematol 1978;7:431-465.
22. Lohrmann HP, Niethammer D, Kern P, et al: Identification of high-risk patients with aplastic anaemia in selection for allogeneic bone-marrow transplantation. Lancet 1976;ii:647-650.
23. Heimpel H: Epidemiology and etiology of aplastic anemia: in Bacigalupo A, Schrezenmeier H (eds): Aplastic Anemia: Pathophysiology and Therapy. Cambridge. Cambridge University Press, 1999, pp 97-116.
24. Camitta BM, Nathan DG, Forman EN, et al: Posthepatitic severe aplastic anemia - an indication for early bone marrow transplantation. Blood 1974;43:473-483.
25. Brown KE, Tisdale J, Barrett AJ, et al: Hepatitis-associated aplastic anemia. N Engl J Med 1997;336:1059-1064.
26. Keisu M, Heit W, Lambertenghi Deliliers G, et al: Transient pancytopenia. A report from the International Agranulocytosis and Aplastic Study. Blut 1990;61:240-244.
27. Heimpel H, Kubanek B: Pathophysiology of aplastic anaemia. Br J Haematol 1975;31 (suppl):57-68.
28. Camitta BM, Storb R, Thomas ED: Aplastic anemia. II. Pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med 1982;306:712-718.
29. Tichelli A, Gratwohl A, Nissen C, et al: Spätkomplikationen bei Patienten mit aplastischer Anämie. Schweiz Med Wochenschr 1988;118: 1528-1532.
30. Tichelli A, Gratwohl A, Nissen C, et al: Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin. Blood 1992;80:337-345.
31. Tichelli A, Gratwohl A, Nissen C, et al: Late clonal complications in severe aplastic anemia. Leuk Lymphoma 1994;12:167-175.
32. De Planque MM, Kluin-Nelemans HC, van Kricken HJ, et al: Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. Br J Haematol 1988;70:55-62.
33. Frickhofen N, Kaltwasser JP, Heimpel H, et al: 10-year results of a German phase III trial evaluation treatment of aplastic anemia with antithymocyte globulin with and without cyclosporin A (abstract), in press.
34. Gordon-Smith E: Treatment of aplastic anemia. 1. Conservative management; in Geary CG (ed): Aplastic Anemia. London, Baillière Tindall, 1979, pp 108-130.
35. The International Agranulocytosis and Aplastic Anemia Study: Incidence of aplastic anemia: The relevance of diagnostic criteria. Blood 1987;70:1718-1821.
36. Heimpel H: Stimulation of hemopoiesis in aplastic anemia by hormones and other agents; in Heimpel H, Gordon-Smith EC, Heit W, et al (eds): Aplastic Anemia - Pathophysiology and Approaches to Therapy. Berlin, Springer, 1979, pp 129-137.
37. Shahidi NT, Diamond I.K: Testosteron-induced remission in aplastic anemia of both acquired and congenital type. N Engl J Med 1961;266:953.
38. Bock EL, Fülle HH, Heimpel H, et al: Die Wirkung von Mesterolone bei Panmyelopathien und renaler Anämie. Med Klin 1976;71:539-547.
39. Branda RF, Amsden TW, Jacob HS: Randomized study of nandrolone therapy for anemias due to bone marrow failure. Arch Intern Med 1977;137:65-69.
40. Camitta BM, Thomas ED: Severe aplastic anaemia: A prospective study of the effect of androgens or transplantation on haematological recovery and survival. Clin Haematol 1978; 7:587-595.
41. Champlin RE, Ho WG, Feig SA, et al: Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood 1985; 66:184-188.
42. Bacigalupo A, Chaple M, Hows J, et al: Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: A randomized trial from the EBMT SAA working party. Br J Haematol 1993;83:145-151.
43. Kaltwasser JP, Dix U, Schalk KP, et al: Effect of androgens on the response to antithymocyte globulin in patients with aplastic anaemia. Eur J Haematol 1988;40:111-118.
44. Najean Y, Pecking A: Androgen therapy in aplastic anemia: short- and long-term results of a cooperative trial in 252 cases: in Najean Y (ed): Medullary Aplasia. New York. Masson, 1980, pp 205-211.
45. Tso SC, Chan TK, Todd D: Aplastic anaemia: A study of prognosis and the effect of androgen therapy. Q J Med 1977;46:513-529.
46. Azen EA, Shahidi NT: Androgen dependency in acquired aplastic anemia. Am J Med 1977; 63:320-324.
47. Pizzuto J, Conte G, Sinco A, et al: Use of androgens in acquired aplastic anaemia. Relation of response to aetiology and severity. Acta Haematol 1980;64:18-24.
48. Olmer J, Carcassonne Y: La splénectomie dans les pancytopénies idiopathiques. Presse Méd 1960;68:857-860.
49. Heaton LD, Croshy WH, Cohen A: Splenectomy in the treatment of hypoplasia of the bone marrow. Ann Surg 1957;146:637.
50. Dreyfus B: A propos de 81 observations de pancytopénies idiopathiques chroniques sans splénomegalie. Rev franc Hématol 1959;14:62.
51. Heimpel H: Die Panmyclopathie und andere Formen der Pancytopenie; in Schwiegk H (ed): Handbuch der Inneren Medizin. Heidelberg, Springer, 1974, pp 83-134.
52. Speck B, Tichelli A, Widmer E, et al: Splenectomy as an adjuvant measure in the treatment of severe aplastic anaemia. Br J Haematol 1996; 92:818-824.
53. Ascensao JL, Pahwa R, Kagan W, et al: Aplastic anaemia: Evidence for an immunological mechanism. Lancet 1976;i:669-671.
54. Heimpel H, Dietrich M, Erdmann H: Azathioprinbehandlung einer kindlichen Panmyelopathie mit schwerer amegakaryozytärer Thrombozytopenie. Verh Dtsch Ges Inn Med 1968; 74:631.